This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on ISI (7)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Dermatology, Other  • Alert me on articles by topic

Arch Dermatol. 1999;135:79-80.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

IN THE 1994 issue of the ARCHIVES in an editorial on rosacea, I described the combination regimen of systemic tetracycline (beginning at 1 g/d in divided doses) and topical metronidazole.¹ Typically, after 1 to 3 months of systemic tetracycline plus topical metronidazole, I can wean patients from the systemic agent completely to the topical metronidazole alone. Knight and Vickers² studied 68 patients who achieved remission with systemic tetracycline. Within 1 month of tetracycline withdrawal, 25% of these patients relapsed. Within 6 months, two thirds of the patients relapsed. In my practice, topical agents, such as metronidazole, appear to maintain the remission at significantly higher levels than those in the untreated patients of Knight and Vickers.

Although not cited by Dahl et al,³ those who follow the rosacea literature will note extensive similarities between the remission-maintaining regimen described and its rationale in my editorial¹ and the protocol and hypothesis in their . . . [Full Text of this Article]

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Azelaic Acid in the Treatment of Papulopustular Rosacea: A Systematic Review of Randomized Controlled Trials.
Liu et al.
Arch Dermatol 2006;142:1047-1052.
ABSTRACT | FULL TEXT  

Rosacea
Powell
NEJM 2005;352:793-803.
FULL TEXT